The present invention relates to a device and method for making sclerosing foam, which is useful in the treatment of varicose veins and other venous conditions. The device comprises a continuous pathway that is at least partly formed of flexible or compressible material and that comprises a foam generating structure within the continuous pathway; the foam generating structure being formed of two or more elements, wherein each element defines at least one passageway of cross sectional area 1 μm2 to 10 mm2 and said two or more elements being arranged in series; a port which allows introduction of material into or extraction of material out of the continuous pathway; and a liquid pathway that is at least partly formed of flexible or compressible material and is arranged to deliver liquid into the foam generating structure between a first and second element of the foam generating structure.

The present disclosure relates to, inter alia, a formulation in a package, the formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.

The invention relates to a composition containing catechins found in green tea, to pharmaceutical compositions and medical devices comprising the composition and to the use of these compositions and medical devices in the treatment of coronavirus infections, especially infection with SARS-CoV-2.

Non-hormonal contraception compositions and methods for contraception are provided. One embodiment provides an antibody or an antigen binding fragment thereof that specifically binds to one or more sperm antigens and inhibits the ability of anti-body-bound sperm to fertilize an egg. Typically, the antibody is a monoclonal antibody, for example a human or humanized monoclonal antibody. In one embodiment, the antibody or antigen binding fragment thereof specifically binds to CD52g expressed on vertebrate, for example human, sperm cells and inhibits, blocks, or reduces the ability of the antibody-bound sperm to fertilize an egg. In one embodiment the antibody contains a membrane anchor. The membrane anchor can contain transmembrane domains, glycosylphosphatidylinositol anchors, or myristoylation motifs.

Non-hormonal contraception compositions and methods for contraception are provided. One embodiment provides an antibody or an antigen binding fragment thereof that specifically binds to one or more sperm antigens and inhibits the ability of anti-body-bound sperm to fertilize an egg. Typically, the antibody is a monoclonal antibody, for example a human or humanized monoclonal antibody. In one embodiment, the antibody or antigen binding fragment thereof specifically binds to CD52g expressed on vertebrate, for example human, sperm cells and inhibits, blocks, or reduces the ability of the antibody-bound sperm to fertilize an egg. In one embodiment the antibody contains a membrane anchor. The membrane anchor can contain transmembrane domains, glycosylphosphatidylinositol anchors, or myristoylation motifs.

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Disclosed herein is a simple method for generation of high-throughput aerosols of monodisperse micro-shell particles. To create the aerosol, small nozzles are employed blowing slightly compressed air on a thin liquid film. This allows one to generate bubble aerosols consisting of particles having a thin liquid shell surrounding a gas core, which are suspended in a carrier gas flow or environment. The diameter of the created liquid shells is uniform and scales with the inner diameter of the blowing nozzle, enabling control on the size of the produced monodispersed aerosol and formation of particles between few microns to several hundred of microns in outer diameter. The process throughput is very high, reaching several thousands of particles with liquid micro-shells per second for one blowing nozzle. The generated aerosol particles are extremely light-weight (few micrograms) and have very small wall thickness (couple of microns), which enables precise delivery of materials and rapid evaporation of solvent in their liquid walls. The process production rate is easily scalable. In terms of possible applications, liquid used for aerosol generation can be enriched with suspended or dissolved materials, for instance by a medical drug for direct delivery into a patient's airways, or by organic/inorganic solvent which solidifies during drying enabling formation of soft or rigid spherical shells out of particles with liquid shells. The blowing gas can have suspended micron/nano particles in it and these particles will be encapsulated by liquid walls of formed micro-shells, which can potentially solidify during their motion, and thus produced aerosols can be used as transport agents for material delivery. Formation of fine monodisperse liquid or solid foams is possible by collecting liquid micro-shells from the generated aerosol on a surface or in a vessel, while the liquid walls of particles of adhere to each other and then can solidify due to solvent evaporation, freezing or polymerization.

The invention relates to a composition comprising apolactoferrin, optionally in admixture with lactoferrin, carried via liposomes, as well as to products comprising such a composition, and to their use for the prevention and/or treatment of the conditions affecting the respiratory system, in particular the viral infections.

The invention relates to a composition comprising apolactoferrin, optionally in admixture with lactoferrin, carried via liposomes, as well as to products comprising such a composition, and to their use for the prevention and/or treatment of the conditions affecting the respiratory system, in particular the viral infections.